Search Results
Real-world PSA responses to apalutamide or enzalutamide in mCSPC
Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC
Apalutamide Plus ADT Leads to Survival Benefit in mCSPC
Comparing real world evidence to phase III data on apalutamide for nmCRPC
PANTHER: apalutamide + abiraterone in Black and White mCRPC patients
Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer
Dr. Saad on the Safety Profile of Apalutamide in M0CRPC
Addressing Current Questions and Controversies in the Management of Prostate Cancer
Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPC
TITAN Phase 3 Trial with Apalutamide in Metastatic Castration Sensitive Prostate Cancer
Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC
ASCO 2024 annual conference highlights
